January 2022 Vol 13, No 1
Looking for inspiring and educational programming for oncology navigators? Look no further than AONN+!
Providing patient education that meets patients’ cultural, literacy, and learning styles can increase patient self-care and satisfaction and improve health outcomes.
Thirty-one biosimilar products have been approved by the FDA, 20 of which have been launched in the United States.
An understanding of the history of racism is required to reduce disparities in cancer care, from investigational research to treatment, agreed a panel that examined barriers to equitable care and potential solutions to remove these barriers.
Oncology therapeutics continue to be a dominant component of the treatment paradigm, and thus, specialized oncology pharmacy programs play an ever-increasing role in the complex delivery of care.
The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months of the COVID-19 pandemic. Here’s what the experts anticipate in the future of telehealth services.
Pandemic-inspired innovations will play an important role in the future of cancer care delivery.
Oncologic drug pricing is being transformed with greater value in mind.
Managing the costs of oncology care while maintaining focus on outcomes of value to patients is increasingly challenging for health plans and self-insured employers who are looking to value-based agreements.
The success of pharma-sponsored oncology support service programs depends on tailoring programs to meet the needs of specific patient populations.
A number of innovative therapies in oncology have made it to market recently, with a wealth of products on the verge of approval.
Results 1 - 11 of 11
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512